Dosing interval of natalizumab in MS: Do good things come to those who wait?

Neurology. 2019 Oct 8;93(15):655-656. doi: 10.1212/WNL.0000000000008238. Epub 2019 Sep 12.

Authors

David B Clifford¹, Kenneth L Tyler²

Affiliations

¹ From the Department of Neurology (D.B.C.), Washington University in St Louis, MO; and Department of Medicine and Immunology-Microbiology (K.L.T.), University of Colorado School of Medicine, Aurora. clifforddb@wustl.edu.
² From the Department of Neurology (D.B.C.), Washington University in St Louis, MO; and Department of Medicine and Immunology-Microbiology (K.L.T.), University of Colorado School of Medicine, Aurora.

PMID: 31515289
DOI: 10.1212/WNL.0000000000008238

No abstract available

Publication types

Editorial
Comment

MeSH terms

Humans
Leukoencephalopathy, Progressive Multifocal*
Multiple Sclerosis*
Natalizumab

Substances

Natalizumab